Suppr超能文献

脲基磺基香豆素衍生物作为选择性强效碳酸酐酶IX和XII抑制剂

Ureidosulfocoumarin Derivatives As Selective and Potent Carbonic Anhydrase IX and XII Inhibitors.

作者信息

Singh Priti, Kumar Sigalapalli Dilep, Sridhar Goud Nerella, Swain Baijayantimala, Kumar Sahoo Santosh, Angeli Andrea, Shaik Afzal B, Madhavi Yaddanapudi Venkata, Supuran Claudiu T, Arifuddin Mohammed

机构信息

Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, 500037, Telangana State, India.

Department of Pharmaceutical Chemistry, Vignan Pharmacy College, Jawaharlal Nehru Technological University, Vadlamudi, 522213, Andhra Pradesh, India.

出版信息

ChemMedChem. 2022 Mar 4;17(5):e202100725. doi: 10.1002/cmdc.202100725. Epub 2021 Dec 23.

Abstract

Owing to severe allergic reactions (anaphylaxis) and resistance exhibited by sulfonamide-based carbonic anhydrase (CA) inhibitors, non-classical or non-sulfonamide CA inhibitors are gaining increased attention by medicinal chemists. In this context, we report the design and synthesis of 30 new non-sulfonamide sulfocoumarin derivatives as CA inhibitors. They were investigated against hCA I and II (cytosolic isozymes) as well as hCA IX and XII (transmembrane, tumor-associated enzymes). All compounds showed prominent selectivity for the tumor-associated isoenzymes hCA IX and XII over the cytosolic isoenzymes hCA I and II. Among all synthesized compounds, 1-(2,2-dioxidobenzo[e][1,2]oxathiin-6-yl)-3-(o-tolyl)urea(5 j)and1-(3-fluorophenyl)-3-(8-methoxy-2,2-dioxidobenzo[e][1,2]oxathiin-6-yl)urea(5 q)were found to be more potent and to have better inhibition constant values against hCA IX than the standard acetazolamide (AAZ), with K values of 23.6 and 23.3 nM, respectively. All other compounds were found to be active under K =920 nM against hCA IX and XII.This study provides a new perspective for the future development of non-sulfonamide derivatives as selective CA inhibitors.

摘要

由于基于磺胺类的碳酸酐酶(CA)抑制剂会引发严重的过敏反应(过敏症)并产生耐药性,非经典或非磺胺类CA抑制剂越来越受到药物化学家的关注。在此背景下,我们报道了30种新型非磺胺类磺基香豆素衍生物作为CA抑制剂的设计与合成。它们针对人CA I和II(胞质同工酶)以及人CA IX和XII(跨膜、肿瘤相关酶)进行了研究。所有化合物对肿瘤相关同工酶hCA IX和XII的选择性均显著高于胞质同工酶hCA I和II。在所有合成化合物中,发现1-(2,2-二氧代苯并[e][1,2]氧硫杂环戊烷-6-基)-3-(邻甲苯基)脲(5 j)和1-(3-氟苯基)-3-(8-甲氧基-2,2-二氧代苯并[e][1,2]氧硫杂环戊烷-6-基)脲(5 q)比标准乙酰唑胺(AAZ)对hCA IX更有效且具有更好的抑制常数,其K值分别为23.6和23.3 nM。发现所有其他化合物在K =920 nM时对hCA IX和XII具有活性。本研究为非磺胺类衍生物作为选择性CA抑制剂的未来发展提供了新的视角。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验